Introduction
Angiogenesis plays an important role in the growth, proliferation, and metastasis of solid tumors. One of the main angiogenic factors is vascular endothelial growth factor (VEGF). VEGF and its receptor (VEGFR) are involved in new blood vessel formation and tumor progression. Therefore, inhibitors of the VEGF pathway could be promising anticancer agents. [1] [2] [3] Several agents that target the angiogenic signal pathway that includes VEGF have been developed. Bevacizumab is a monoclonal antibody, targeting VEGF-A, which was approved for the treatment of multiple solid tumors, including metastatic colorectal cancer (mCRC), nonesmall-cell lung cancer, ovarian cancer, renal cell cancer, and recurrent glioblastoma. 4 Bevacizumab and other tyrosine kinase inhibitors (TKIs) that target VEGF pathway, such as sunitinib or sorafenib, can cause gastrointestinal (GI) perforation and fistula formation (Table 1) . [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] Regorafenib, an oral multikinase inhibitor, targets multiple pathways, including those involving VEGFR1-3, TIE2 (tyrosine kinase with immunoglobulin and epidermal growth factor homology domain 2), KIT, platelet-derived growth factor receptor, and RET (rearranged during transfection) tyrosine kinase. Inhibition of the VEGF pathway can increase the risk of serious adverse events such as gastrointestinal (GI) perforation and fistula formation. 19, 20 Only a few cases of GI perforation or fistula have been reported among patients taking regorafenib. 21 Fistula occurred in 4 of 500 cases (0.8%) in the phase III COR-RECT (regorafenib monotherapy for previously treated metastatic colorectal cancer) trial for mCRC. GI perforation developed in 1 of 136 patients (0.7%) in the phase III CONCUR (regorafenib plus best supportive care vs. placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer) trial for mCRC and in 2 of 188 patients (1.1%) in the phase III GRID (efficacy and safety of regorafenib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib) trial for
Clinical Practice Points
Regorafenib is an oral multikinase inhibitor that targets multiple pathways, including vascular endothelial growth factor receptor, and improves the survival of patients with metastatic colorectal cancer (mCRC). Gastrointestinal (GI) perforation and fistula are wellrecognized adverse events associated with agents that target the VEGF pathway, including bevacizumab. We report 5 cases of GI perforation or fistula formation during treatment with regorafenib.
We identified 1 case of GI perforation (0.6%) and 4 cases of fistula formation (2.4%) among 170 patients with mCRC administered regorafenib in our hospital. In all 5 cases, GI perforation or fistula involved the residual tumor and were successfully treated with antibiotic therapy or surgery and recovered from these adverse events. It is important to recognize that GI perforation and fistula can occur in patients treated with regorafenib.
advanced gastrointestinal stromal tumor. 13, 14, 22, 23 A description of the trials of agents that target the VEGF pathway and reports of GI perforation and fistula are presented in Table 1 . However, we are still not sufficiently aware of these events during regorafenib treatment in the routine clinical practice setting. We report 5 cases of GI perforation or fistula formation during regorafenib treatment to clarify the characteristics and clinical course of patients who developed these adverse events during treatment or within 30 days of the last administration of regorafenib.
Case Report
We retrospectively analyzed the data from 170 patients with mCRC who had received regorafenib from May 2013 to March 2016 at the National Cancer Center Hospital East. We identified 1 patient with GI perforation (0.6%) and 4 with fistula formation (2.4%; Table 2 ). Of the 5 patients, 3 were men and 2 were women. Their median age was 59 years (range, 44-78 years). All 5 patients had Eastern Cooperative Oncology Group performance status of 0 or 1. The primary tumor had been previously resected in 3 cases, and the location of the residual primary tumor or local recurrence was the rectum in 3 cases and the colon in 2. Of the 5 patients, 3 had peritoneum metastases. All 5 patients had previously received 2 lines of chemotherapy, including bevacizumab, and 1 patient had received previous abdominal irradiation.
In all 5 patients, GI perforation or fistula involved the residual tumor, 3 at the site of the primary tumor or local recurrence in the rectum and 2 at the site of the primary tumor in the transverse colon or jejunum, which was involved by peritoneal metastases. An abscess and Fournier's gangrene due to the fistula were observed between the tumor and perineum in the 3 patients with rectal cancer. A representative fistula formation case is presented in Figure 1 . A computed tomography scan of the patient with jejunum perforation showed tumor shrinkage in the peritoneal metastasis with regorafenib treatment and, in addition, free air in the abdominal cavity (Figure 2 ). Using the Response Evaluation Criteria in Solid Tumors, all 5 patients had radiologically stable disease with regorafenib treatment.
The median interval between the onset of GI perforation or fistula formation and the initiation of regorafenib was 20 days (range, 5-84 days). These events occurred during regorafenib treatment in 4 patients and 8 days after termination of regorafenib in 1 patient. The median interval between the last administration of bevacizumab as previous treatment and the onset of GI perforation or fistula formation was 71 days (range, 29-107 days), and all events occurred > 34 weeks after the initiation of bevacizumab treatment. The main symptoms for these events were fever and pain. Three patients underwent emergency surgery with debridement. The other 2 patients received antibiotic treatment, and 1 required additional surgery; thus, 4 patients underwent surgery. All 5 patients recovered from these adverse events, with a median time from onset to recovery of 13 days. No deaths related to the GI perforation or fistula occurred. Two patients underwent subsequent chemotherapy. One patient was alive > 1 year later, and the other 4 patients died of disease progression, with a median survival of 6 months (range, 3-20 months) after GI perforation and fistula formation.
Discussion
We have reported the clinical characteristics of 5 patients, 4 with GI fistula and 1 with perforation, who underwent treatment of mCRC with regorafenib. The incidence of these adverse events was similar to the incidence in previous reports related to the administration of bevacizumab or other TKIs. All 5 patients had received bevacizumab before treatment with regorafenib. However, we speculate that these adverse events were related to regorafenib rather than bevacizumab, because it was reported that GI perforation and fistula related to bevacizumab occurred within 15 weeks after the initiation of bevacizumab treatment. 24 In contrast, our patients developed perforation or fistula > 34 weeks after the initiation of bevacizumab treatment. In addition, the estimated half-life of bevacizumab is approximately 20 days; however, our cases occurred > 29 days after the last dose of bevacizumab. Therefore, we considered that a reasonable causal relationship exists between these adverse events and regorafenib. Several mechanism for GI perforation resulting from VEGF inhibition have been proposed, including (1) decreased capillary density in the intestinal mucosa and regeneration of the normal mucosa, depending on nitric oxide and prostacyclin involving VEGF; (2) shrinkage and necrosis of the tumor infiltrating the intestinal mucosa in response to treatment; (3) bowel ischemia by thrombosis or cholesterol embolism syndrome of the mesenteric vessels; and (4) regression of normal blood vessels. 24 Other risk factors for GI perforation include bowel surgery, abdominal irradiation, colonoscopy within 1 month, peptic ulcer disease, administration of nonsteroidal anti-inflammatory drugs or steroids, an intact primary tumor, abdominal carcinomatosis, bowel obstruction, diverticulosis, and chemotherapy-induced colitis. 19, 24 A recent study reported that, in contrast to previous reports, only a residual primary tumor, abdominal irradiation, and age < 65 years were associated with GI perforation. 25, 26 Similarly, 2 patients in our study had residual primary tumor, 1 patient had previously undergone abdominal irradiation, and 4 patients were aged < 65 years.
Stenosis and the accumulation of feces owing to residual tumor, which results in increased inner pressure of the bowel itself, could have been associated with fistula formation in the 3 patients with rectal tumors. Therefore, we supposed that perforation and fistula would tend to occur in the rectum when the tumor remained during treatment with regorafenib. It was reported that GI perforation might occur in response to treatment. 20 We found shrinkage of the peritoneal metastasis in the 1 patient with GI perforation. Precise analyses of the value of peritoneal metastasis and residual primary tumor as risk factors for GI perforation or fistula warrant further evaluation.
Conclusion
It remains unclear whether VEGFR-TKIs, including regorafenib, increase the risk of GI perforation, because, unlike bevacizumab, a meta-analysis of VEGFR-TKIs indicated that no difference existed in the frequency of GI perforation between the TKI and control arms. 27 However, the meta-analysis results might have been influenced by the inclusion of fewer cases with abdominal primary tumors in the analysis of the TKIs (58%) compared with the analysis of bevacizumab (74%). 17, 27 In addition, because regorafenib inhibits some mechanisms of tumor vascularization that differ from those inhibited by bevacizumab, some differences could exist in the characteristics of perforation. Further analysis using a larger sample size is necessary to clarify the role of VEGFR-TKIs as risk factors for GI perforation or fistula and the clinical characteristics, because we had a small sample enrolled from a single institution. Finally, all the patients in our study complained of fever and/or pain, which were adequately treated by antibiotic treatment or surgery. Some studies of regorafenib and other TKIs have reported cases of treatment-related death from these adverse events. 21, 28 Thus, if patients experience fever or pain during or after regorafenib therapy, we should pay careful attention to the cause of these adverse events.
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